Actively Recruiting
A Causal Role for Voltage-gated Cav1.2 Calcium Channels in Mediating 5G FR1 Effects on Sleep-associated Brain Health in Humans
Led by Hans-Peter Landolt · Updated on 2025-05-31
30
Participants Needed
1
Research Sites
110 weeks
Total Duration
On this page
Sponsors
H
Hans-Peter Landolt
Lead Sponsor
F
Federal Office for the Environment, Switzerland
Collaborating Sponsor
AI-Summary
What this Trial Is About
Electromagnetic fields (EMFs) generated by the use of 5G technology influence certain sleep characteristics, especially in individuals carrying a specific genetic variant of a protein in the brain that regulates the activity of nerve cells. This protein is a voltage-gated calcium channel called CaV1.2 and could be involved in the effects of 5G technology on sleep. The calcium channel CaV1.2 can be selectively blocked by the drug nimodipine. To demonstrate that CaV1.2 is indeed involved in the effects of 5G technology on sleep, the researchers are investigating in this study, with healthy subjects carrying the sought-after genetic variant, whether the administration of nimodipine and thus the blockade of the calcium channel before exposure mitigates or eliminates the effects of EMF on sleep health.
CONDITIONS
Official Title
A Causal Role for Voltage-gated Cav1.2 Calcium Channels in Mediating 5G FR1 Effects on Sleep-associated Brain Health in Humans
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged between 20 and 40 years
- Able to read and write German and/or English
- Provided informed consent with signature
- Completed the first part of this study or a related precursor study
- Carry the CACNA1C rs7304986 T/C allele
- Male participants included
- Female participants must use hormonal contraception during the study
- Right-handedness
- Body Mass Index between 17.0 and 26.0 kg/m2
- Moderate alcohol use (less than 5 drinks per week)
- Moderate caffeine use (less than 3 caffeinated items per day)
- Provided informed consent with signature
You will not qualify if you...
- Travel across more than 2 time zones in the last 30 days or during the study
- Night shift work
- Extreme sleep patterns or habitual sleep less than 5 or more than 10 hours per night
- Known sleep disorders or diseases
- Serious neurological, mental, or general medical conditions posing risk or affecting measurements
- Use of medications affecting study measurements
- Use of illegal drugs
- Smoking or other tobacco use
- Suspected non-compliance with study instructions
- Inability to follow study procedures due to language, psychological, or cognitive issues
- Severe skin allergies or hypersensitivities
- Participation in another clinical trial within 30 days before or during this study
- Known allergy or contraindication to nimodipine
- Other conditions discouraging use of nimodipine
- Pregnancy or breastfeeding
- Intention to become pregnant during the study
- Lack of reliable contraception for females of childbearing potential
- Sleep apnea or nocturnal myoclonus index of 5 or more per hour
- Sleep efficiency below 80% on screening night
- Other findings during screening that pose risk or affect measurements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Zurich, Institute of Pharmacology and Toxicology
Zurich, Canton of Zurich, Switzerland, 8057
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
24
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here